Concepts (172)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiovascular Diseases | 10 | 2016 | 333 | 1.170 |
Why?
|
| Antihypertensive Agents | 6 | 2009 | 70 | 1.170 |
Why?
|
| Hypertension | 7 | 2009 | 217 | 1.100 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 5 | 2009 | 24 | 0.670 |
Why?
|
| Myocardial Infarction | 4 | 2004 | 134 | 0.640 |
Why?
|
| Coronary Disease | 5 | 2004 | 51 | 0.570 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2008 | 43 | 0.540 |
Why?
|
| Hypertrophy, Left Ventricular | 8 | 2015 | 15 | 0.500 |
Why?
|
| Calcium Channel Blockers | 2 | 2006 | 33 | 0.500 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2015 | 13 | 0.490 |
Why?
|
| Regeneration | 1 | 2015 | 20 | 0.490 |
Why?
|
| Neovascularization, Physiologic | 1 | 2015 | 17 | 0.490 |
Why?
|
| Cardiomyopathies | 1 | 2015 | 32 | 0.480 |
Why?
|
| Stem Cell Transplantation | 1 | 2015 | 40 | 0.480 |
Why?
|
| Heart | 1 | 2015 | 56 | 0.480 |
Why?
|
| Stroke | 3 | 2010 | 254 | 0.460 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2003 | 27 | 0.420 |
Why?
|
| Hypolipidemic Agents | 2 | 2003 | 21 | 0.420 |
Why?
|
| Acute Coronary Syndrome | 3 | 2014 | 15 | 0.350 |
Why?
|
| Humans | 34 | 2016 | 26010 | 0.340 |
Why?
|
| Risk Factors | 11 | 2015 | 2242 | 0.330 |
Why?
|
| Heart Defects, Congenital | 1 | 2010 | 23 | 0.330 |
Why?
|
| Ramipril | 1 | 2009 | 1 | 0.320 |
Why?
|
| Benzoates | 1 | 2009 | 5 | 0.320 |
Why?
|
| Benzimidazoles | 1 | 2009 | 9 | 0.320 |
Why?
|
| United States | 11 | 2015 | 1975 | 0.310 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2008 | 305 | 0.300 |
Why?
|
| Ventricular Dysfunction, Left | 5 | 2011 | 39 | 0.290 |
Why?
|
| Arteriosclerosis | 2 | 2005 | 9 | 0.270 |
Why?
|
| Oxazoles | 1 | 2006 | 2 | 0.260 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 1 | 2006 | 3 | 0.260 |
Why?
|
| Drug Approval | 1 | 2006 | 7 | 0.260 |
Why?
|
| United States Food and Drug Administration | 1 | 2006 | 22 | 0.260 |
Why?
|
| Glycine | 1 | 2006 | 12 | 0.260 |
Why?
|
| Angina, Unstable | 2 | 2014 | 9 | 0.240 |
Why?
|
| American Heart Association | 2 | 2014 | 18 | 0.240 |
Why?
|
| Coronary Artery Bypass | 2 | 2014 | 23 | 0.240 |
Why?
|
| Echocardiography | 6 | 2015 | 79 | 0.230 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2015 | 173 | 0.230 |
Why?
|
| Heart Failure | 2 | 2004 | 167 | 0.230 |
Why?
|
| Captopril | 1 | 2004 | 1 | 0.230 |
Why?
|
| Perindopril | 1 | 2004 | 1 | 0.230 |
Why?
|
| Tetrazoles | 1 | 2004 | 2 | 0.230 |
Why?
|
| Cardiology | 2 | 2014 | 43 | 0.230 |
Why?
|
| Valine | 1 | 2004 | 6 | 0.230 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2004 | 9 | 0.230 |
Why?
|
| Vitamins | 1 | 2004 | 19 | 0.230 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 3 | 2009 | 3 | 0.230 |
Why?
|
| Indoles | 1 | 2004 | 34 | 0.220 |
Why?
|
| Verapamil | 1 | 2004 | 26 | 0.220 |
Why?
|
| Pravastatin | 1 | 2003 | 2 | 0.210 |
Why?
|
| Losartan | 1 | 2003 | 2 | 0.210 |
Why?
|
| Heptanoic Acids | 1 | 2003 | 3 | 0.210 |
Why?
|
| Carbazoles | 1 | 2003 | 6 | 0.210 |
Why?
|
| Propanolamines | 1 | 2003 | 8 | 0.210 |
Why?
|
| Metoprolol | 1 | 2003 | 7 | 0.210 |
Why?
|
| Prevalence | 6 | 2010 | 433 | 0.210 |
Why?
|
| Carotid Artery Diseases | 1 | 2003 | 15 | 0.210 |
Why?
|
| Pyrroles | 1 | 2003 | 22 | 0.210 |
Why?
|
| Dietary Supplements | 1 | 2003 | 55 | 0.210 |
Why?
|
| Antioxidants | 1 | 2003 | 55 | 0.200 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2003 | 68 | 0.200 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2002 | 36 | 0.200 |
Why?
|
| Incidence | 4 | 2015 | 713 | 0.180 |
Why?
|
| Risk Assessment | 6 | 2016 | 622 | 0.180 |
Why?
|
| Atrial Fibrillation | 1 | 2003 | 132 | 0.180 |
Why?
|
| Anti-Bacterial Agents | 1 | 2003 | 338 | 0.170 |
Why?
|
| Metabolic Syndrome | 2 | 2015 | 55 | 0.170 |
Why?
|
| Critical Care | 1 | 2002 | 190 | 0.170 |
Why?
|
| Blood Glucose | 3 | 2011 | 99 | 0.160 |
Why?
|
| Treatment Outcome | 4 | 2009 | 3292 | 0.150 |
Why?
|
| Diabetes Mellitus | 4 | 2009 | 126 | 0.150 |
Why?
|
| Blood Pressure | 3 | 2015 | 194 | 0.150 |
Why?
|
| Diabetic Angiopathies | 2 | 2015 | 6 | 0.140 |
Why?
|
| Drug Therapy, Combination | 2 | 2009 | 170 | 0.140 |
Why?
|
| Ventricular Function, Left | 2 | 2009 | 36 | 0.140 |
Why?
|
| Follow-Up Studies | 4 | 2015 | 1711 | 0.130 |
Why?
|
| Body Mass Index | 2 | 2015 | 412 | 0.120 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2014 | 24 | 0.120 |
Why?
|
| Multicenter Studies as Topic | 2 | 2004 | 52 | 0.110 |
Why?
|
| Disease Management | 1 | 2014 | 108 | 0.110 |
Why?
|
| Prognosis | 3 | 2015 | 750 | 0.110 |
Why?
|
| Heart Conduction System | 2 | 2003 | 10 | 0.110 |
Why?
|
| Aged | 11 | 2015 | 8702 | 0.110 |
Why?
|
| Female | 14 | 2015 | 14388 | 0.100 |
Why?
|
| Double-Blind Method | 2 | 2004 | 399 | 0.100 |
Why?
|
| Male | 13 | 2015 | 14000 | 0.100 |
Why?
|
| Middle Aged | 12 | 2016 | 8503 | 0.100 |
Why?
|
| Insulin Resistance | 1 | 2011 | 45 | 0.090 |
Why?
|
| Indians, North American | 1 | 2010 | 6 | 0.090 |
Why?
|
| Electrocardiography | 3 | 2014 | 104 | 0.090 |
Why?
|
| Echocardiography, Doppler | 1 | 2009 | 15 | 0.080 |
Why?
|
| Diastole | 1 | 2009 | 28 | 0.080 |
Why?
|
| Global Health | 1 | 2009 | 37 | 0.080 |
Why?
|
| Animals | 2 | 2006 | 3389 | 0.080 |
Why?
|
| Risk Reduction Behavior | 1 | 2009 | 42 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 315 | 0.080 |
Why?
|
| Tunica Intima | 2 | 2004 | 9 | 0.070 |
Why?
|
| Comorbidity | 4 | 2014 | 465 | 0.070 |
Why?
|
| Atherosclerosis | 1 | 2006 | 49 | 0.070 |
Why?
|
| Coronary Angiography | 2 | 2004 | 68 | 0.060 |
Why?
|
| Body Height | 1 | 2005 | 33 | 0.060 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2004 | 4 | 0.060 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2004 | 18 | 0.060 |
Why?
|
| Carotid Stenosis | 1 | 2004 | 4 | 0.060 |
Why?
|
| Databases, Factual | 1 | 2006 | 324 | 0.060 |
Why?
|
| Tunica Media | 1 | 2004 | 4 | 0.060 |
Why?
|
| Carotid Artery, Common | 1 | 2004 | 4 | 0.060 |
Why?
|
| Fluorocarbons | 1 | 2004 | 10 | 0.060 |
Why?
|
| Valsartan | 1 | 2004 | 1 | 0.060 |
Why?
|
| Heart Ventricles | 1 | 2004 | 86 | 0.060 |
Why?
|
| Homocysteine | 1 | 2004 | 5 | 0.060 |
Why?
|
| Albumins | 1 | 2004 | 18 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2006 | 568 | 0.060 |
Why?
|
| Contrast Media | 1 | 2004 | 60 | 0.060 |
Why?
|
| Cohort Studies | 5 | 2011 | 1821 | 0.060 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2003 | 31 | 0.050 |
Why?
|
| Adult | 4 | 2016 | 7358 | 0.050 |
Why?
|
| Ultrasonography | 4 | 2006 | 222 | 0.050 |
Why?
|
| Cerebrovascular Disorders | 1 | 2005 | 132 | 0.050 |
Why?
|
| Atenolol | 1 | 2003 | 1 | 0.050 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2003 | 69 | 0.050 |
Why?
|
| Cholesterol, LDL | 1 | 2003 | 25 | 0.050 |
Why?
|
| Reproducibility of Results | 3 | 2016 | 670 | 0.050 |
Why?
|
| Sensitivity and Specificity | 4 | 2004 | 485 | 0.050 |
Why?
|
| Coronary Artery Disease | 1 | 2004 | 127 | 0.050 |
Why?
|
| Physician's Role | 1 | 2002 | 17 | 0.050 |
Why?
|
| Mississippi | 2 | 2016 | 3 | 0.050 |
Why?
|
| Critical Illness | 1 | 2002 | 122 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2005 | 1140 | 0.040 |
Why?
|
| Systole | 2 | 2009 | 15 | 0.040 |
Why?
|
| Forecasting | 1 | 2016 | 90 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2015 | 1658 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2016 | 77 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 2015 | 16 | 0.030 |
Why?
|
| Albuminuria | 1 | 2015 | 14 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2014 | 52 | 0.030 |
Why?
|
| Sex Factors | 2 | 2006 | 442 | 0.030 |
Why?
|
| Organ Size | 2 | 2004 | 95 | 0.030 |
Why?
|
| Socioeconomic Factors | 2 | 2004 | 290 | 0.030 |
Why?
|
| Disease Progression | 1 | 2015 | 685 | 0.030 |
Why?
|
| Fasting | 1 | 2011 | 13 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2009 | 295 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 4658 | 0.020 |
Why?
|
| Normal Distribution | 1 | 2004 | 5 | 0.020 |
Why?
|
| Raloxifene Hydrochloride | 1 | 2004 | 2 | 0.020 |
Why?
|
| Lipoproteins, HDL | 1 | 2004 | 21 | 0.020 |
Why?
|
| Young Adult | 1 | 2011 | 1852 | 0.020 |
Why?
|
| Cerebellum | 1 | 2005 | 40 | 0.020 |
Why?
|
| Postmenopause | 1 | 2004 | 49 | 0.010 |
Why?
|
| Cholesterol | 1 | 2004 | 43 | 0.010 |
Why?
|
| Ultrasonography, Doppler | 1 | 2004 | 14 | 0.010 |
Why?
|
| ROC Curve | 1 | 2004 | 132 | 0.010 |
Why?
|
| Reference Values | 1 | 2004 | 184 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2005 | 101 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 96 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2004 | 326 | 0.010 |
Why?
|
| Smoking | 1 | 2004 | 169 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 335 | 0.010 |
Why?
|
| Observer Variation | 1 | 2003 | 93 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2004 | 252 | 0.010 |
Why?
|
| Thrombolytic Therapy | 1 | 2002 | 46 | 0.010 |
Why?
|
| Obesity | 1 | 2005 | 277 | 0.010 |
Why?
|
| Acute Disease | 1 | 2002 | 189 | 0.010 |
Why?
|
| Biomarkers | 1 | 2004 | 549 | 0.010 |
Why?
|
| Patient Discharge | 1 | 2002 | 146 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2004 | 853 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2004 | 929 | 0.010 |
Why?
|
| Algorithms | 1 | 2002 | 358 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2004 | 1340 | 0.010 |
Why?
|
| Hospitalization | 1 | 2002 | 292 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2005 | 3294 | 0.010 |
Why?
|